Marktanalyse - Bacterial Pneumonia - Pipeline Review, H2 2016

Global Markets Direct
12.2016
212 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Bacterial Pneumonia - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Pneumonia — Pipeline Review, H2 2016, provides an overview of the Bacterial Pneumonia (Infectious Disease) pipeline landscape.

Bacterial pneumonia is an infection in one or both lungs. The bacteria cause the lung’s air sacs (alveoli) to become inflamed and engorged with pus, fluid, and cellular debris. This often impairs the body’s ability to exchange oxygen and carbon dioxide. Predisposing factors are age, long-term users of immunosuppressant drugs, chronic obstructive pulmonary disease (COPD) patients who use inhaled corticosteroids for lengthy periods and smokers. Symptoms include cough with yellow, green, or blood-tinged mucus, headache, muscle pain, breathlessness or rapid breathing, lethargy and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Pneumonia — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 8, 13, 2, 30, 12 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 9 and 6 molecules, respectively.

Bacterial Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Bacterial Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacterial Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacterial Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Pneumonia (Infectious Disease)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacterial Pneumonia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacterial Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 5

Bacterial Pneumonia Overview 6

Therapeutics Development 7

Bacterial Pneumonia - Therapeutics under Development by Companies 9

Bacterial Pneumonia - Therapeutics under Investigation by Universities/Institutes 12

Bacterial Pneumonia - Pipeline Products Glance 13

Bacterial Pneumonia - Products under Development by Companies 17

Bacterial Pneumonia - Products under Investigation by Universities/Institutes 21

Bacterial Pneumonia - Companies Involved in Therapeutics Development 22

Bacterial Pneumonia - Therapeutics Assessment 65

Drug Profiles 75

Bacterial Pneumonia - Dormant Projects 185

Bacterial Pneumonia - Discontinued Products 190

Bacterial Pneumonia - Product Development Milestones 191

Appendix 201





List of Tables

Number of Products under Development for Bacterial Pneumonia, H2 2016 17

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Development, H2 2016 25

Comparative Analysis by Unknown Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Development by Companies, H2 2016 (Contd..3) 30

Products under Investigation by Universities/Institutes, H2 2016 31

Bacterial Pneumonia - Pipeline by Abera Bioscience AB, H2 2016 32

Bacterial Pneumonia - Pipeline by Actelion Ltd, H2 2016 33

Bacterial Pneumonia - Pipeline by Affinivax Inc, H2 2016 34

Bacterial Pneumonia - Pipeline by Allergan Plc, H2 2016 35

Bacterial Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 36

Bacterial Pneumonia - Pipeline by Arsanis Inc, H2 2016 37

Bacterial Pneumonia - Pipeline by AstraZeneca Plc, H2 2016 38

Bacterial Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 39

Bacterial Pneumonia - Pipeline by Biken Inc, H2 2016 40

Bacterial Pneumonia - Pipeline by ContraFect Corp, H2 2016 41

Bacterial Pneumonia - Pipeline by Crestone Inc, H2 2016 42

Bacterial Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 43

Bacterial Pneumonia - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 44

Bacterial Pneumonia - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 45

Bacterial Pneumonia - Pipeline by Emergent BioSolutions Inc, H2 2016 46

Bacterial Pneumonia - Pipeline by FluGen Inc, H2 2016 47

Bacterial Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016 48

Bacterial Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016 49

Bacterial Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016 50

Bacterial Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016 51

Bacterial Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 52

Bacterial Pneumonia - Pipeline by Lascco SA, H2 2016 53

Bacterial Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016 54

Bacterial Pneumonia - Pipeline by LG Life Science LTD, H2 2016 55

Bacterial Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016 56

Bacterial Pneumonia - Pipeline by MedImmune LLC, H2 2016 57

Bacterial Pneumonia - Pipeline by Merck & Co Inc, H2 2016 58

Bacterial Pneumonia - Pipeline by Mucosis BV, H2 2016 59

Bacterial Pneumonia - Pipeline by Noxxon Pharma AG, H2 2016 60

Bacterial Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016 61

Bacterial Pneumonia - Pipeline by Pfizer Inc, H2 2016 62

Bacterial Pneumonia - Pipeline by Polyphor Ltd, H2 2016 63

Bacterial Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016 64

Bacterial Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016 65

Bacterial Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016 66

Bacterial Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016 67

Bacterial Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016 68

Bacterial Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 69

Bacterial Pneumonia - Pipeline by Valneva SE, H2 2016 70

Bacterial Pneumonia - Pipeline by Vaxxilon AG, H2 2016 71

Bacterial Pneumonia - Pipeline by Virometix AG, H2 2016 72

Bacterial Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016 73

Bacterial Pneumonia - Pipeline by Wockhardt Ltd, H2 2016 74

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Stage and Target, H2 2016 78

Number of Products by Stage and Mechanism of Action, H2 2016 80

Number of Products by Stage and Route of Administration, H2 2016 82

Number of Products by Stage and Molecule Type, H2 2016 84

Bacterial Pneumonia - Dormant Projects, H2 2016 195

Bacterial Pneumonia - Dormant Projects (Contd..1), H2 2016 196

Bacterial Pneumonia - Dormant Projects (Contd..2), H2 2016 197

Bacterial Pneumonia - Dormant Projects (Contd..3), H2 2016 198

Bacterial Pneumonia - Dormant Projects (Contd..4), H2 2016 199

Bacterial Pneumonia - Discontinued Products, H2 2016 200





List of Figures

Number of Products under Development for Bacterial Pneumonia, H2 2016 17

Number of Products under Development for Bacterial Pneumonia - Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Products, H2 2016 25

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Top 10 Targets, H2 2016 77

Number of Products by Stage and Top 10 Targets, H2 2016 77

Number of Products by Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Routes of Administration, H2 2016 81

Number of Products by Stage and Routes of Administration, H2 2016 81

Number of Products by Top 10 Molecule Types, H2 2016 83

Number of Products by Stage and Top 10 Molecule Types, H2 2016 83

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus